BioMap (BioMap), a global leader in foundational large models for life sciences, and Harbour BioMed(Stock Code:02142.HK），a global biopharmaceutical company focused on the discovery and development of innovative antibody therapies for immune diseases, oncology, and other areas, jointly announced today thatBoth Partieswill be establishedA Multi-Layered, Long-Term Comprehensive Strategic Partnership，Around complex macromolecular drugsAIR&D to carry out comprehensive collaboration,Aimed at systematically addressing the bottlenecks and challenges in the research and development of next-generation innovative therapies,Jointly create a globallyLeadingCompetitiveR&D Ecosystem。

Strategic Cooperation Framework，The two parties will jointly establish a new type of company targeting the global marketAIPipeline R&D Company—MegaStream TechBio。The company will integrate "exclusive big data×Exclusive Large Language Model×Large Innovative Pipeline Portfolio"，Building a new-generation intelligent dry-wet closed-loop experimental platform andPersonalized,centered on multimodal, multi-attribute generative large modelsAIR&D Engine. Focused on major unmet clinical needs in cardiovascular, renal, anti-aging, and oncology areas, withFirst-in-Class（FIC）andBest-in-Class（BIC）as the core benchmark, develop next-generation frontier complex macromolecular drugs with global competitiveness, and systematically advance differentiated innovative pipelines into clinical stages, dedicated toTo become a global leader in complex macromolecules AI Benchmark Enterprise in Drug R&D。

Harbour BioMed will serve as the lead initiator, forMegaStreamOpen its globally unique fully human antibody platform, extensive target biology expertise, and global clinical development advantages; BioMap will serve as a co-initiator, providing the underlyingAITechnology Empowerment, Model Engineering Support, and Intelligent R&D Capabilities to Accelerate the Company's Rapid ProgressPipeline R&D Progress.MegaStreamThe initial pipeline consists of the two parties' previous collaborativeAIDrug R&D Projects and Newly InitiatedAIjointly constitute the native pipeline R&D project. The two initiators shall be entitled to potential upfront payments, success-based milestones, and royalty sharing in accordance with industry practices. Meanwhile,MegaStream The core management team will be jointly formed by senior executives from multinational pharmaceutical companies and leading experts in the field of artificial intelligence, with relevant personnel gradually assuming their positions.

AsMegaStream TechBioCo-initiator，Harbour BioMed and BioMap to Join Forces in Advancing Three Core Strategic Initiatives：

I. Establishing a Globally Leading ExclusiveAIDDInfrastructurePlatform, Defining the Next-Generation Underlying Engineering Paradigm for Complex Macromolecules

Both parties willMegaStreamCreate a globally leadingAIDriving Complex Macromolecular DrugsAIDDInfrastructurePlatform.The platform will be built upon BioMap’s leading large foundation model platform for life sciences.xTrimo, andHarbour BioMed’s ExclusiveHarbour Mice^®The vast amount of high-quality data accumulated by the fully human antibody platform.

In this strategic collaboration, BioMap will leverage its foundational large model capabilities in life sciences, combined with the high-quality comprehensive data provided by Harbour BioMed, to conduct systematic, targeted training, optimization, and iteration, addressing the distinct characteristics of complex macromolecular drugs versus traditional general-purpose protein and antibody therapeutics.Forming a personalized, exclusive solution with continuous self-evolution capabilitiesMegaStreamLargeModel. As the company's AI foundation,This model will be oriented toward next-generation multispecific antibodies,XDCConjugated Drugs, In VivoCAR-T, Inhalation/Deep optimization of complex macromolecules, including oral biologics, delivers robust performance advantages and enables an end-to-end solution from sequence generation to developability optimization.AIDesign capability.

II. Co-building Next-Generation IntelligenceHigh-Throughput Dry-Wet Closed-Loop Laboratory, forAIEfficient Validation of Native Molecules and Continuous Data Accumulation Provide Closed-Loop Assurance

WithMegaStreamLarge Language Modelas the foundation, both parties will leverage Harbour BioMed’s extensive proprietary experimental technology capabilities, as well as BioMapBioMap OSIdentifying the system’s advantages in high-throughput dry-wet closed-loop laboratory scheduling management, automated data analysis, data management, and model iteration,Construction of a New-Generation Intelligent High-Throughput Dry-Wet Closed-Loop Laboratory.

To address the needs for model training and validation of various biological attribute parameters of complex macromolecular drugs, as well as the practical requirements for data accumulation and model iteration during drug development, this laboratory will establish a globally leading intelligent control hub and experimental capability system, achieving breakthroughs in four core capabilities: fully intelligent scheduling, high-performance experimental validation, automated collection and analysis of comprehensive data, and high-efficiencyAIModeling and Model Evolution, Forming"Design-Construction-Test-Learning"End-to-End Automated Closed-Loop System.

ThisAIUpon completion, the Native Intelligence Laboratory is expected to achieve higher efficiency compared to the previous generation of dry-wet closed-loop laboratories.500%The above will significantly accelerate the discovery and iteration pace of complex macromolecular drugs, driving a fundamental transformation in R&D paradigms andAIContinuous optimization of model capabilities provides strong support. Meanwhile, the laboratory will increase data accumulation efficiency by more than10times, expected to generate over the next five years5PBof high qualityAI-ReadyLife Science Data, DrivingAIThe model evolves rapidly and effectively.

III. Empowering the scalable development of a next-generation pipeline portfolio,Achieve from“AIGenerate”to“Clinical Value”End-to-End Closed Loop

The First of Both PartiesAI+Biotechnology-DrivenFirst-in-ClassPipeline R&D collaboration commenced in2021Year,and in the subsequent 10+ pipeline projects, continuously empowering key R&D stages such as property prediction, optimization, and generative design through AI. In the future, relying on the newly built next-generationAIComplex Macromolecule Drug R&D Platform,FIC/BICThe R&D capabilities of the pipeline will be significantly enhanced, for Harbour BioMed andMegaStreamParallel AdvancementSupported by hundreds of innovative pipeline projects. ThroughAIModel prediction combined with a small amount of high-precision validation, replacingTraditional Repetitive Screening Assays, and leveraging the generative predictive advantages of large models to produce high-caliber pipeline molecules with superior performance metrics, more comprehensive attribute optimization, and more precise programmable controllability. In the coming years,Both parties will accelerate the development of their existing pipelines and newFIC/BICthe clinical translation progress of the pipeline, building an industry-leading fromAIA complete value chain closed loop from R&D to clinical implementation.

Founder, Chairman, and Chief Executive Officer of Harbour BioMedMegaStream TechBioDr. Wang Jinsong, Chairman, stated:"The strategic partnership between Harbour BioMed and BioMap marksAIDriven biomedical innovation has entered a brand-new stage. Harbour BioMed possesses a globally leading fully human antibody technology platform and over a decade of accumulated proprietary high-quality antibody data, while BioMap boasts a world-class life science foundation large model with hundreds of billions of parameters andAIComputing Platform. This powerful collaboration not only affirms and upgrades the successful partnership between the two parties but also systematically accelerates the global development of next-generation innovative complex macromolecular drugs.Speed and Success Rate。MegaStreamComplete company formation and the initial implementation of the first pipeline within the shortest possible timeframe, adopting a practical approach to successfully execute fromAIAn innovative closed-loop from design to clinical validation, we also look forward to joining hands with global long-term partners and top-tier investment institutions to jointly explore new industrial opportunities."

Co-founder of BioMap,CEOLiu Wei stated："BioMap has been committed to building cutting-edge biological fields since its establishmentAIPredictive capabilities, with the aim of helping pharmaceutical companies build solutions capable of supporting large-scaleFICA comprehensive platform that enables generative discovery and supports the joint prediction of multiple attribute parameters to identify optimal candidates from early research through preclinical stages. Harbour BioMed is a benchmark enterprise in the field of fully human antibodies, with itsHarbour Mice^®Platform andHu-mAtrIx™ AIThe platform represents the cutting-edge direction of deep integration between antibody engineering and artificial intelligence. This strategic collaboration combines BioMap’s large model capabilities with Harbour BioMed’s proprietary data assets and extensive drug development expertise, creating a tripartite generative biomedical system.AIInfrastructure. We believe that this infrastructure will, through high-volumeFICThe successful development of the pipeline demonstrates significant value and brings a paradigm-levelAISetting a New Benchmark for Applications."